文献速递MDS 与骨髓增殖性肿瘤贫血与红细胞疾病

小剂量地西他滨治疗较低危骨髓增生异常综合征结局的初步研究

[A preliminary study on the outcome of lower-risk myelodysplastic syndrome by low-dose decitabine].
PubMed 文献 · Zhonghua Xue Ye Xue Za Zhi · 2017-01-01

浙江省4所医院纳入62例较低危MDS患者,分为小剂量地西他滨组(12 mg·m⁻²·d⁻¹连续5 d)与支持治疗组。可评估51例中地西他滨组ORR为66.7%对支持治疗组29.6%(P=0.008),中位PFS未达到对13.7个月(P=0.037);地西他滨组3~4级中性粒细胞减少45.8%、3~4级感染33.3%(8/24)。

要点

  • 地西他滨组ORR 66.7%对支持治疗组29.6%(P=0.008)。
  • 地西他滨组中位PFS未达到对支持治疗组13.7个月(P=0.037)。
  • 基因突变阳性(除单纯SF3B1)患者中位PFS 9.2个月对阴性18.5个月(P=0.008)。

核心结论

  • 小系列患者的初步结果表明小剂量地西他滨治疗较低危MDS患者可能有效,对于基因突变患者也可获益,且患者耐受,值得临床试验进一步明确其临床意义。

研究设计与样本

  • 浙江省4所医院开展的研究,纳入62例新诊断较低危MDS患者,分为地西他滨组(12 mg·m⁻²·d⁻¹连续5 d)与支持治疗组(BSC)。
  • 检测骨髓样本中MDS相关15项基因突变,主要终点为至少2个周期后的总体有效率(ORR)及无进展生存(PFS)与基因突变的相关性。

主要发现

  • 62例入组患者中51例纳入最终分析,地西他滨组24例、支持治疗组27例。
  • 地西他滨组ORR为66.7%(16/24),支持治疗组为29.6%(8/27),χ²=6.996,P=0.008。
  • 地西他滨组中位PFS未达到,支持治疗组为13.7个月,差异有统计学意义(P=0.037)。
  • 51例中20例(39.2%)检出至少一种基因突变,其中4例为单纯SF3B1突变。
  • 基因突变阳性(不包括单纯SF3B1突变)患者中位PFS为9.2个月,短于无基因突变者的18.5个月(P=0.008);ORR分别为37.5%对58.1%(P=0.181)。

关键数值与推荐

  • 地西他滨组3~4级中性粒细胞减少发生率为45.8%。
  • 地西他滨组3~4级感染发生率为33.3%(8/24)。

临床怎么用

  • 作者认为小剂量地西他滨治疗较低危MDS患者可能有效,对于基因突变患者也可获益,且患者耐受。
  • 作者认为值得临床试验进一步明确其临床意义。

局限性

  • 原文结论称该研究为小系列患者的初步结果。
  • 原文结论提出值得临床试验进一步明确其临床意义。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: To assess the efficiency and safety of low-dose decitabine in patients with lower-risk myelodysplastic syndrome (MDS) to couple with the clinical significance of MDS-related gene mutations. Methods: This study was done in 4 institutions in Zhejiang Province. A total of 62 newly diagnosed patients with lower-risk MDS were assigned to two groups of decitabine (12 mg·m(-2)·d(-1) for 5 consecutive days) and best supportive care (BSC) . Their bone marrow samples were subject to examinations of MDS-related 15 gene mutations. The primary endpoints were the proportion of patients who achieved overall response (ORR) after at least two cycles and progression-free survival (PFS) , and their relevances to the gene mutations. Results: Of 62 enrolled patients, and 51 cases were included in the final analysis. 16 of 24 patients (66.7%) in decitabine group achieved ORR versus 8 of 27 (29.6%) in BSC group (χ(2)=6.996, P=0.008) ; PFS prolongation of decitabine versus BSC was statistically significant (not reached vs 13.7 months, P=0.037) . Among 51 patients, at least one gene mutation was identified in 20 patients (39.2%) , including 4 single SF3B1 mutation. PFS in cases with gene mutations (not including single SF3B1 mutation) was significantly shorter than of no gene mutation (9.2 months vs 18.5 months, P=0.008) , but not for ORR (37.5% vs 58.1%, P=0.181) . Among 16 patients with mutated genes, ORR in decitabine and BSC groups were 75% (6/8) and 0 (0/8) , respectively. The most adverse events in decitabine group were grade 3 to 4 neutropenia (45.8%) and grade 3 to 4 infections (33.3%) . Conclusion: This preliminary study showed that low-dose decitabine produced promising results with an acceptable safety in lower-risk MDS patients, especially for those with mutated genes. Further study targeting poor prognostic lower-risk MDS patients should be warranted. 目的: 评价小剂量地西他滨治疗较低危骨髓增生异常综合征(MDS)患者的初步疗效及安全性,探讨MDS相关基因突变的临床意义。 方法: 纳入浙江省4所医院收治的62例较低危MDS患者,治疗分2组,地西他滨组(地西他滨12 mg·m(-2)·d(-1),连续5 d)和支持治疗组,检测与MDS预后相关的15项基因突变情况。比较两组患者的总体有效率(ORR)和无进展生存(PFS)时间,分析其与基因突变的相关性。 结果: 62例患者中,可评估患者51例,其中地西他滨组24例,支持治疗组27例。与支持治疗组相比,地西他滨组的ORR(66.7%对29.6%,χ(2)=6.996,P=0.008)和中位PFS时间显著改善(未达到对13.7个月,P=0.037)。51例患者中20例(39.2%)检测到基因突变阳性,其中4例患者单纯SF3B1阳性,均在支持治疗组。与基因突变阴性患者相比,16例基因突变阳性(除单纯SF3B1阳性)患者中位PFS时间显著缩短(9.2个月对18.5个月,P=0.008),其中地西他滨组8例患者中6例有效,支持治疗组无一例(0/8)有效。地西他滨治疗期间主要不良反应为3~4级粒细胞减少(45.8%),3~4级感染发生率为33.3%(8/24)。 结论: 该研究小系列患者的初步结果表明应用小剂量地西他滨治疗较低危MDS患者可能有效,对于基因突变患者也可获益,且患者耐受,值得临床试验进一步明确其临床意义。.

来源:Zhonghua Xue Ye Xue Za Zhi,查看原文。版权归原作者所有。

引用

  1. Ye L, Ren YL, Xie LL, et al. [A preliminary study on the outcome of lower-risk myelodysplastic syndrome by low-dose decitabine]. Zhonghua Xue Ye Xue Za Zhi. 2017. PMID: 28468092. doi:10.3760/cma.j.issn.0253-2727.2017.04.009

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。